Armata Adds Pfizer Veteran to Board as It Pushes Phage Therapeutics
Event summary
- Armata Pharmaceuticals appointed Daniel B. Gilmer, Ph.D., Senior Director at Pfizer, to its Board of Directors on April 24, 2026.
- Gilmer led the U.S. launch of Pfizer's PAXLOVID and has expertise in commercializing anti-infective therapies.
- Gilmer is a co-inventor on the patent for Exebacase, a first-in-class bacteriophage lysin.
- Armata focuses on developing bacteriophage therapeutics for antibiotic-resistant infections.
The big picture
Armata's appointment of Daniel B. Gilmer reflects its push to strengthen commercialization capabilities as it advances phage therapeutics. Gilmer's background in launching anti-infectives and his co-invention of Exebacase provide Armata with strategic insights into both the scientific and market challenges of addressing antibiotic resistance. The move underscores the growing importance of phage therapy in the biotech landscape, particularly as traditional antibiotics face increasing resistance.
What we're watching
- Commercialization Strategy
- How Gilmer's experience with PAXLOVID will shape Armata's approach to bringing phage therapeutics to market.
- Regulatory Pathways
- Whether Armata can leverage Gilmer's insights to navigate FDA approvals for its phage-based pipeline.
- Industry Leadership
- The pace at which Armata can establish itself as a leader in the emerging phage therapy space.
Related topics